Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.

Mathieu C, Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M.

Diabetes Ther. 2013 Dec;4(2):285-308. doi: 10.1007/s13300-013-0037-8.


Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.

Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, Salaun-Martin C, Sapin H, Bruhn D, Mathieu C, Theodorakis M.

Diabetes Metab Syndr Obes. 2013 Apr 26;6:171-85. doi: 10.2147/DMSO.S41827.


Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.

Kiiskinen U, Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Theodorakis M, Kiljański J, Salaun-Martin C, Sapin H, Guerci B.

Clinicoecon Outcomes Res. 2013 Jul 11;5:355-67. doi: 10.2147/CEOR.S44060.


Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.

Reaney M, Mathieu C, Ostenson CG, Matthaei S, Krarup T, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M, Guerci B.

Health Qual Life Outcomes. 2013 Dec 26;11:217. doi: 10.1186/1477-7525-11-217.


Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study.

Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Guerci B, Kiljanski J, Petto H, Bruhn D, Theodorakis M.

Diabetes Ther. 2012 Nov;3(1):6. doi: 10.1007/s13300-012-0006-7.


Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.

Buse JB, Han J, Miller S, MacConell L, Pencek R, Wintle M.

Curr Med Res Opin. 2014 Jul;30(7):1209-18. doi: 10.1185/03007995.2014.896329.


Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.

Miller LA, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert VF, Bruhn D.

J Med Econ. 2012;15(4):746-57. doi: 10.3111/13696998.2012.679756.


The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.

de Lapertosa SB, Frechtel G, Hardy E, Sauque-Reyna L.

Diabetes Res Clin Pract. 2016 Dec;122:38-45. doi: 10.1016/j.diabres.2016.10.001.


Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.

Yoon NM, Cavaghan MK, Brunelle RL, Roach P.

Clin Ther. 2009 Jul;31(7):1511-23. doi: 10.1016/j.clinthera.2009.07.021.


Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes.

Bounthavong M, Tran JN, Golshan S, Piland NF, Morello CM, Blickensderfer A, Best JH.

Diabetes Metab. 2014 Sep;40(4):284-91. doi: 10.1016/j.diabet.2014.06.002.


Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.

Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group..

Curr Med Res Opin. 2009 Jan;25(1):65-75. doi: 10.1185/03007990802597951 .


Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.


Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting.

Bergenstal RM, Garrison LP Jr, Miller LA, Hou L, Blickensderfer A, Zagar A, Stanley S, Bhargava A, Wade R, Herman WH.

Curr Med Res Opin. 2011 Dec;27(12):2335-42. doi: 10.1185/03007995.2011.628305.


Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia.

Gallwitz B, Böhmer M, Segiet T, Mölle A, Milek K, Becker B, Helsberg K, Petto H, Peters N, Bachmann O.

Diabetes Care. 2011 Mar;34(3):604-6. doi: 10.2337/dc10-1900.


Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.

Pawaskar M, Tuttle KR, Li Q, Best JH, Anderson PW.

Ann Pharmacother. 2014 May;48(5):571-6. doi: 10.1177/1060028013520597.


Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.

Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Faries D, Engelman W, Bruhn D, Bergenstal RM.

Diabetes Obes Metab. 2012 Jul;14(7):626-33. doi: 10.1111/j.1463-1326.2012.01581.x.


Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.

Matyjaszek-Matuszek B, Lenart-Lipińska M, Rogalska D, Nowakowski A; GWAA Polish Study Group..

Endokrynol Pol. 2013;64(5):375-82. doi: 10.5603/EP.2013.0021.


Effectiveness of exenatide in Asian Indians in a clinical care setting.

Sudhakaran C, Fathima M, Anjana RM, Unnikrishnan RI, Mohan V.

Diabetes Technol Ther. 2010 Aug;12(8):613-8. doi: 10.1089/dia.2010.0033.


Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J.

Ann Intern Med. 2011 Jan 18;154(2):103-12. doi: 10.7326/0003-4819-154-2-201101180-00300.

Items per page

Supplemental Content

Support Center